luc.stoppini 580193647 Stoppini Luc luc.stoppini@hesge.ch fr 1 Off On

{"id":7878435,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":7345,"title":"Dispositifs nanostructur\u00e9s pour la r\u00e9g\u00e9n\u00e9ration neuronale\r\n","description":"Le projet mettra au point des substrats \u00e0 base d'oxyde de titane dop\u00e9 au niobium (TiO2:Nb) favorisant la croissance neuronale. Ces oxydes, \u00e0 la fois conducteurs et transparants, permettront d'investiguer les m\u00e9canismes de croissance par stimulation \u00e9lectrique et photonique. Partenaires : Universit\u00e9 de Besan\u00e7on, ABCD Technology, 3D-Oxides. Projet InterREG, du 1 juillet 2013 au 31 d\u00e9cembre 2014.    \r\n\r\nPour DT : Montage du projet au taux de EUR 1.20"},"en":{"id":7346,"title":"Dispositifs nanostructur\u00e9s pour la r\u00e9g\u00e9n\u00e9ration neuronale\r\n","description":"Le projet mettra au point des substrats \u00e0 base d'oxyde de titane dop\u00e9 au niobium (TiO2:Nb) favorisant la croissance neuronale. Ces oxydes, \u00e0 la fois conducteurs et transparants, permettront d'investiguer les m\u00e9canismes de croissance par stimulation \u00e9lectrique et photonique. Partenaires : Universit\u00e9 de Besan\u00e7on, ABCD Technology, 3D-Oxides. Projet InterREG, du 1 juillet 2013 au 31 d\u00e9cembre 2014.    \r\n\r\nPour DT : Montage du projet au taux de EUR 1.20"},"de":{"id":7347,"title":"Dispositifs nanostructur\u00e9s pour la r\u00e9g\u00e9n\u00e9ration neuronale\r\n","description":"Le projet mettra au point des substrats \u00e0 base d'oxyde de titane dop\u00e9 au niobium (TiO2:Nb) favorisant la croissance neuronale. Ces oxydes, \u00e0 la fois conducteurs et transparants, permettront d'investiguer les m\u00e9canismes de croissance par stimulation \u00e9lectrique et photonique. Partenaires : Universit\u00e9 de Besan\u00e7on, ABCD Technology, 3D-Oxides. Projet InterREG, du 1 juillet 2013 au 31 d\u00e9cembre 2014.    \r\n\r\nPour DT : Montage du projet au taux de EUR 1.20"}},"id":37679,"acronym":"NANOBIUM","mainTitle":"Dispositifs nanostructur\u00e9s pour la r\u00e9g\u00e9n\u00e9ration neuronale\r\n","mainDescription":"Le projet mettra au point des substrats \u00e0 base d'oxyde de titane dop\u00e9 au niobium (TiO2:Nb) favorisant la croissance neuronale. Ces oxydes, \u00e0 la fois conducteurs et transparants, permettront d'investiguer les m\u00e9canismes de croissance par stimulation \u00e9lectrique et photonique. Partenaires : Universit\u00e9 de Besan\u00e7on, ABCD Technology, 3D-Oxides. Projet InterREG, du 1 juillet 2013 au 31 d\u00e9cembre 2014.    \r\n\r\nPour DT : Montage du projet au taux de EUR 1.20","value":"135600.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7878434,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"marc.jobin","project":37679},{"id":7878435,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":37679}],"dataHub":true,"startAt":"2013-07-01T00:00:00+02:00","endAt":"2015-03-31T00:00:00+02:00","fundingSource":"INTERREG IV; hepia inSTI; INTERREG GE; INTERREG VD; ABCD; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7869879,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":9319,"title":"\"integrated Neurotoxicity Testing for Electrophysiological and Neurocellular \r\nand Seizurogenic Effects\"\r\n","description":"The project entitled 'integrated Neurotoxicity Testing for Electrophysiological and Neurocellular and Seizurogenic Effects' (iNTENSE) will deliver a human stem cell (hiPSC)-based platform, as an alternative to animal models, to test new chemicals... to replace animal models in testing new chemicals with neurotoxic, neuroactive and seizurogenic effects. This platform will be physiologically relevant by incorporating the features of current neurotoxicity testing in animals and improve on current state-of-art by offering high throughout and high content platforms. In the first mode, neuron-glia co-cultures will be screened in medium-throughput for electrophysiological changes using Microelectrode Arrays (MEAs). In this mode, hundreds to thousands of compounds can be tested per month. Based on their functional profiles, compounds can enter mode 2 high-content analysis, which integrates electrophysiological, morphological and structural data to provide an accurate dosage data (ED50) and mechanistic information. Both analytic modes will be commercialized as a platform service to the pharmaceutical industry to be offered as a contract research organisation (CRO). In phase 1 of the project we will present a Proof-of-Concept by demonstrating the capabilities of mature MEA-active hiPSC cultures; a complexity within our neural cell population equivalent to hippocampal slices; activity within complex 3D co-cultures; pilot tests with offered neurotoxins and pro-convulsants; a scalable capacity of our MEA platform up to 96-well capacity and pathophysiological validation by comparison to adult human brain tissue. In project phase 2, all of the components will be integrated into a single platform and workflow. This will include development of standard operating procedure (SOP); inclusion of hiPSCs from female and male donors to monitor potential sex-related differences in neurotoxic\/seizurogenic effects, hiPSC engineering to incorporate fluorescent and luminescent markers to provide cell analysis within the platform, analytical software writing and extensive QC testing of the product.\r\n"},"en":{"id":9320,"title":"\"integrated Neurotoxicity Testing for Electrophysiological and Neurocellular \r\nand Seizurogenic Effects\"\r\n","description":"The project entitled 'integrated Neurotoxicity Testing for Electrophysiological and Neurocellular and Seizurogenic Effects' (iNTENSE) will deliver a human stem cell (hiPSC)-based platform, as an alternative to animal models, to test new chemicals... to replace animal models in testing new chemicals with neurotoxic, neuroactive and seizurogenic effects. This platform will be physiologically relevant by incorporating the features of current neurotoxicity testing in animals and improve on current state-of-art by offering high throughout and high content platforms. In the first mode, neuron-glia co-cultures will be screened in medium-throughput for electrophysiological changes using Microelectrode Arrays (MEAs). In this mode, hundreds to thousands of compounds can be tested per month. Based on their functional profiles, compounds can enter mode 2 high-content analysis, which integrates electrophysiological, morphological and structural data to provide an accurate dosage data (ED50) and mechanistic information. Both analytic modes will be commercialized as a platform service to the pharmaceutical industry to be offered as a contract research organisation (CRO). In phase 1 of the project we will present a Proof-of-Concept by demonstrating the capabilities of mature MEA-active hiPSC cultures; a complexity within our neural cell population equivalent to hippocampal slices; activity within complex 3D co-cultures; pilot tests with offered neurotoxins and pro-convulsants; a scalable capacity of our MEA platform up to 96-well capacity and pathophysiological validation by comparison to adult human brain tissue. In project phase 2, all of the components will be integrated into a single platform and workflow. This will include development of standard operating procedure (SOP); inclusion of hiPSCs from female and male donors to monitor potential sex-related differences in neurotoxic\/seizurogenic effects, hiPSC engineering to incorporate fluorescent and luminescent markers to provide cell analysis within the platform, analytical software writing and extensive QC testing of the product.\r\n"},"de":{"id":9321,"title":"\"integrated Neurotoxicity Testing for Electrophysiological and Neurocellular \r\nand Seizurogenic Effects\"\r\n","description":"The project entitled 'integrated Neurotoxicity Testing for Electrophysiological and Neurocellular and Seizurogenic Effects' (iNTENSE) will deliver a human stem cell (hiPSC)-based platform, as an alternative to animal models, to test new chemicals... to replace animal models in testing new chemicals with neurotoxic, neuroactive and seizurogenic effects. This platform will be physiologically relevant by incorporating the features of current neurotoxicity testing in animals and improve on current state-of-art by offering high throughout and high content platforms. In the first mode, neuron-glia co-cultures will be screened in medium-throughput for electrophysiological changes using Microelectrode Arrays (MEAs). In this mode, hundreds to thousands of compounds can be tested per month. Based on their functional profiles, compounds can enter mode 2 high-content analysis, which integrates electrophysiological, morphological and structural data to provide an accurate dosage data (ED50) and mechanistic information. Both analytic modes will be commercialized as a platform service to the pharmaceutical industry to be offered as a contract research organisation (CRO). In phase 1 of the project we will present a Proof-of-Concept by demonstrating the capabilities of mature MEA-active hiPSC cultures; a complexity within our neural cell population equivalent to hippocampal slices; activity within complex 3D co-cultures; pilot tests with offered neurotoxins and pro-convulsants; a scalable capacity of our MEA platform up to 96-well capacity and pathophysiological validation by comparison to adult human brain tissue. In project phase 2, all of the components will be integrated into a single platform and workflow. This will include development of standard operating procedure (SOP); inclusion of hiPSCs from female and male donors to monitor potential sex-related differences in neurotoxic\/seizurogenic effects, hiPSC engineering to incorporate fluorescent and luminescent markers to provide cell analysis within the platform, analytical software writing and extensive QC testing of the product.\r\n"}},"id":49605,"acronym":"iNTENSE","mainTitle":"\"integrated Neurotoxicity Testing for Electrophysiological and Neurocellular \r\nand Seizurogenic Effects\"\r\n","mainDescription":"The project entitled 'integrated Neurotoxicity Testing for Electrophysiological and Neurocellular and Seizurogenic Effects' (iNTENSE) will deliver a human stem cell (hiPSC)-based platform, as an alternative to animal models, to test new chemicals... to replace animal models in testing new chemicals with neurotoxic, neuroactive and seizurogenic effects. This platform will be physiologically relevant by incorporating the features of current neurotoxicity testing in animals and improve on current state-of-art by offering high throughout and high content platforms. In the first mode, neuron-glia co-cultures will be screened in medium-throughput for electrophysiological changes using Microelectrode Arrays (MEAs). In this mode, hundreds to thousands of compounds can be tested per month. Based on their functional profiles, compounds can enter mode 2 high-content analysis, which integrates electrophysiological, morphological and structural data to provide an accurate dosage data (ED50) and mechanistic information. Both analytic modes will be commercialized as a platform service to the pharmaceutical industry to be offered as a contract research organisation (CRO). In phase 1 of the project we will present a Proof-of-Concept by demonstrating the capabilities of mature MEA-active hiPSC cultures; a complexity within our neural cell population equivalent to hippocampal slices; activity within complex 3D co-cultures; pilot tests with offered neurotoxins and pro-convulsants; a scalable capacity of our MEA platform up to 96-well capacity and pathophysiological validation by comparison to adult human brain tissue. In project phase 2, all of the components will be integrated into a single platform and workflow. This will include development of standard operating procedure (SOP); inclusion of hiPSCs from female and male donors to monitor potential sex-related differences in neurotoxic\/seizurogenic effects, hiPSC engineering to incorporate fluorescent and luminescent markers to provide cell analysis within the platform, analytical software writing and extensive QC testing of the product.\r\n","value":"30205.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1863744,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1863745,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7869879,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":49605}],"dataHub":true,"startAt":"2015-02-01T00:00:00+01:00","endAt":"2015-05-31T00:00:00+02:00","fundingSource":"Neurix SA","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7869791,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":4651,"title":"Multiparametric of engineered tissues from embryonic stem cells (ESCs) : tools for \"Human-based in vitro testing systems\" and \"organ replacement\".","description":"The main goal of the present project is to create biologically inspired artificial micro-organs from embryonic stem cells to mimic some features of a complex organism. The expected outcome of this project is the development of a \"Multi-Organs-on-a-Chip\" platform. This technology will serve as the base for the construction of biochips for in vitro drug and toxicological screenings as well as to design biomedical devices that will help to restore or replace organ functions in the future."},"en":{"id":4652,"title":"Multiparametric of engineered tissues from embryonic stem cells (ESCs) : tools for \"Human-based in vitro testing systems\" and \"organ replacement\".","description":"The main goal of the present project is to create biologically inspired artificial micro-organs from embryonic stem cells to mimic some features of a complex organism. The expected outcome of this project is the development of a \"Multi-Organs-on-a-Chip\" platform. This technology will serve as the base for the construction of biochips for in vitro drug and toxicological screenings as well as to design biomedical devices that will help to restore or replace organ functions in the future."},"de":{"id":4653,"title":"Multiparametric of engineered tissues from embryonic stem cells (ESCs) : tools for \"Human-based in vitro testing systems\" and \"organ replacement\".","description":"The main goal of the present project is to create biologically inspired artificial micro-organs from embryonic stem cells to mimic some features of a complex organism. The expected outcome of this project is the development of a \"Multi-Organs-on-a-Chip\" platform. This technology will serve as the base for the construction of biochips for in vitro drug and toxicological screenings as well as to design biomedical devices that will help to restore or replace organ functions in the future."}},"id":23747,"acronym":"Stem-3d","mainTitle":"Multiparametric of engineered tissues from embryonic stem cells (ESCs) : tools for \"Human-based in vitro testing systems\" and \"organ replacement\".","mainDescription":"The main goal of the present project is to create biologically inspired artificial micro-organs from embryonic stem cells to mimic some features of a complex organism. The expected outcome of this project is the development of a \"Multi-Organs-on-a-Chip\" platform. This technology will serve as the base for the construction of biochips for in vitro drug and toxicological screenings as well as to design biomedical devices that will help to restore or replace organ functions in the future.","value":"270400.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1863674,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"519,Economie d'entreprise","class":"academique"},{"id":1863675,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"Microtechnologies appl.","class":"academique"},{"id":1863676,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"VS - Institut Sciences du vivant","class":"academique"},{"id":1863677,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7869773,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"anne.walker","project":23747},{"id":7869774,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"olivier.walpen","project":23747},{"id":7869775,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"stephane.bourquin","project":23747},{"id":7869776,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":23747},{"id":7869777,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"wilfried.andlauer","project":23747},{"id":7869778,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"martial.geiser","project":23747},{"id":7869779,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"oksana.banakh","project":23747},{"id":7869780,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"catherin.csefalva","project":23747},{"id":7869781,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"stephan.ramseyer","project":23747},{"id":7869782,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"fabrice.bisoffi","project":23747},{"id":7869783,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"frederic.truffer","project":23747},{"id":7869784,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"patrick.gexfabry","project":23747},{"id":7869785,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"charles.brack","project":23747},{"id":7869786,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"gilles.triscone","project":23747},{"id":7869787,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"jerome.charmet","project":23747},{"id":7869788,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"philippe.passerau","project":23747},{"id":7869789,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"bruno.schnyder","project":23747},{"id":7869790,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"herve.eusebe","project":23747},{"id":7869791,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":23747},{"id":7869792,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"valerie.duay","project":23747},{"id":7869793,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"edith.laux","project":23747},{"id":7869794,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laure.jeandupe","project":23747}],"dataHub":true,"startAt":"2009-09-01T00:00:00+02:00","endAt":"2012-01-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7868425,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":10342,"title":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","description":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n"},"en":{"id":10343,"title":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","description":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n"},"de":{"id":10344,"title":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","description":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n"}},"id":66637,"acronym":"NanoReg2","mainTitle":"\"Development and implementation of Grouping\r\nand Safe-by-Design approaches within regulatory frameworks (NanoREG II)\".\r\n","mainDescription":"\"One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the well-known principle of the half-life of facts (Samuel Arbesman, 2012) means that what is an accepted truth now is no longer valid in 20 or 30 years time. The challenge\r\nis to build a regulatory system which is flexible enough to be able to deal with new targets and requirements in the future, and this can be helped by the development and introduction of Safe by Design (SbD) principles.\r\nThe credibility of such a regulatory system, underpinned by the implementation of SbD, is essential for industry, who while accepting the need for regulation demand it is done in a cost effective and rapid manner.\r\nThe NANoREG II project, built around the challenge of coupling SbD to the regulatory process, will demonstrate and establish new principles and ideas based on data from value chain implementation studies to establish SbD as a fundamental pillar in the validation of a novel MNM.\r\nIt is widely recognized by industries as well as by regulatory agencies that grouping strategies for NM are urgently needed. ECETOC has formed a task force on NM grouping and also within the OECD WPMN a group works on\r\nNM categorisation. However, so far no reliable and regulatory accepted grouping concepts could be established\".\r\n","value":"365098.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1863326,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"GE Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture","class":"academique"},{"id":1863327,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1863328,"name":null,"confidential":false,"types":[{"id":2,"code":"TER"},{"id":5,"code":"TERRAIN"}],"institution":"Partenaires NanoReg2","class":"professionnel"},{"id":1863329,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7868422,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"michael.minelli","project":66637},{"id":7868423,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":66637},{"id":7868424,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":66637},{"id":7868425,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":66637}],"dataHub":true,"startAt":"2016-03-10T00:00:00+01:00","endAt":"2019-02-28T00:00:00+01:00","fundingSource":"SEFRI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7868229,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":9580,"title":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","description":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n"},"en":{"id":9581,"title":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","description":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n"},"de":{"id":9582,"title":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","description":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n"}},"id":51307,"acronym":"I1 - MEAZURE","mainTitle":"D\u00e9veloppement d'un appareil permettant le monitoring en continu de tissus nerveux ainsi que de barri\u00e8res biologiques : mod\u00e9lisation de l'unit\u00e9 neurovasculaire.\r\n","mainDescription":"\"As the world's population is aging, diseases of the central nervous system (CNS) become an increasing threat for global health. The total annual cost resulting from CNS diseases is quickly escalating. While considered a public health priority by the World Health Organization, the development of drugs against these diseases fails to succeed. CNS drugs have one of the highest failure rates and longest development times. One reason for this poor success is that CNS drugs have to cross the blood brain barrier (BBB) before reaching the neural tissue. Many promising substances with proven effects in in vitro models fail in human because they cannot cross the BBB or are denatured by the crossing. This complexity is worsened by the fact that there is currently no in vitro system to test simultaneously whether a substance can cross the human BBB and adequately affect the adjacent human neural tissue. \r\nThe project MEAZURE addresses this problem. We will develop a device allowing the tissue engineering of an artificial human neurovascular unit (NVU), i.e. an in vitro model comprising both the neural tissue and the BBB. This device will allow the simultaneous monitoring of the two components of the model and their pharmacological testing. This innovative solution aims at increasing the success rate of CNS drug development by facilitating and speeding up the drug discovery process and to screen potential neurotoxic molecules present in our environment. \r\nMEAZURE is a collaborative effort of 5 groups of the HES-SO. The main deliverable is a device combining a system to record simultaneously neuronal activity with a system to measure the blood-brain barrier permeability. A Micro-Electrode Array (MEA) unit will allow the electrophysiological recording of neural cultures sitting at the bottom of a standard 24-well plate and a Trans Endothelial Electrical Resistance (TEER) unit allowing the recording of the electrical impedance of a cultured BBB positioned just above. Both systems will be developed and assembled using the HES-SO competences and correspond to adaptations and improvements of home-made technologies. We have maximized innovation to deliver a fully operational and efficient product. The device will be a unique stand-alone system able to work autonomously in an incubator, data being transmitted wirelessly or stored locally within the device. The device is also versatile and amenable for MEA recording, TEER recording or both. Finally it has medium-throughput capacities, it is compatible with industrial use and it will be proposed at international level for R&D or commercial use. \r\n\"\r\n","value":"211600.00","finished":true,"pilier":6,"url":null,"keywords":"Bio-impedance, Blood brain barrier, Central nervous system, Drug discovery, Neurotoxicity","disciplines":[],"axes":[],"partners":[{"id":1863244,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"ReDS","class":"academique"},{"id":1863245,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"VS - Institut Sciences du vivant","class":"academique"},{"id":1863246,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1863247,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"FR - EIA - Institut IPRINT","class":"academique"},{"id":1863248,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"Technologie d'interaction","class":"academique"},{"id":1863249,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7868218,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"lorenzo.pirrami","project":51307},{"id":7868219,"role":"CO","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"aicha.rizzotti","project":51307},{"id":7868220,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"anne.walker","project":51307},{"id":7868221,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"yann.thoma","project":51307},{"id":7868222,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"rick.wertenbr","project":51307},{"id":7868223,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"roland.scherwey","project":51307},{"id":7868224,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":51307},{"id":7868225,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"mike.meury","project":51307},{"id":7868226,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":51307},{"id":7868227,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"bruno.schnyder","project":51307},{"id":7868228,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"marco.mazza","project":51307},{"id":7868229,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":51307}],"dataHub":true,"startAt":"2015-12-15T00:00:00+01:00","endAt":"2017-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7868197,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":9451,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":9452,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":9453,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":53966,"acronym":"SCAHT-6","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"168500.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7868194,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":53966},{"id":7868195,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":53966},{"id":7868196,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":53966},{"id":7868197,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":53966}],"dataHub":true,"startAt":"2016-01-01T00:00:00+01:00","endAt":"2016-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7788410,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":11143,"title":"SpikeOnChip: Analyse on-line et on-chip d'activit\u00e9 neuronale","description":"The last decade has witnessed a renewed interest for in vitro approaches in the fields of drug discovery and\r\ntoxicity testing. One very promising approach is the use of engineered human neural tissue fabricated from iPS\r\ncells. To ensure the rapidity of the tests in neural tissues the traditional chemical, cytosolic and histologic read-\r\nouts have been replaced by an electrophysiological read-out, i.e. the recording of the electrical activity of\r\nneurons using smart Petri dishes that incorporate electrode arrays. A big challenge for recording such activity\r\nis the very large amount of data generated by the electrode arrays, resulting in cumbersome and long data\r\nanalysis to be performed in order to get the final experimental results, and the reliability of the systems.\r\nWithin this context, the aim of the SpikeOnChip project is to develop a platform for efficient processing and\r\nstorage of neuronal spike activities. It will not only offer recording of observed electrodes (up to 64), but also\r\nan on-chip analysis that will allow to reduce the quantity of data by a factor of 20x, by selecting only the\r\ninteresting portions. The platform will be based on a ZedBoard embedding a Zynq (FPGA + ARM processor in\r\none die). This data reduction will allow to save memory, and as a result allow the system to run autonomously\r\nfor a longer period of time. Connection will be supplied by a Wifi link in order to transfer data to a PC, however\r\ngaining autonomy will imply a more reliable system in the sense that if the connection is lost at some point,\r\ndata can be stored for up to 3 hours without losing any important information.\r\nData acquisition will be done by an Intan chip that translates raw voltages from the electrode array onto serial\r\ndigital data that is sent to an FPGA. The processing performed on-chip will consist in signal filtering of the raw\r\ndata, spike detection, noise rejection, and field potential frequency analysis.\r\nFinally a software will also be developed so as to let a user control the embedded platform and to visualize the\r\nanalysis results.\r\nThis project will imply a validation stage, performed by biologists, to ensure the system not only works with\r\nrespect to the specifications, but is also usable by end users."},"en":{"id":11144,"title":"SpikeOnChip: Analyse on-line et on-chip d'activit\u00e9 neuronale","description":"The last decade has witnessed a renewed interest for in vitro approaches in the fields of drug discovery and\r\ntoxicity testing. One very promising approach is the use of engineered human neural tissue fabricated from iPS\r\ncells. To ensure the rapidity of the tests in neural tissues the traditional chemical, cytosolic and histologic read-\r\nouts have been replaced by an electrophysiological read-out, i.e. the recording of the electrical activity of\r\nneurons using smart Petri dishes that incorporate electrode arrays. A big challenge for recording such activity\r\nis the very large amount of data generated by the electrode arrays, resulting in cumbersome and long data\r\nanalysis to be performed in order to get the final experimental results, and the reliability of the systems.\r\nWithin this context, the aim of the SpikeOnChip project is to develop a platform for efficient processing and\r\nstorage of neuronal spike activities. It will not only offer recording of observed electrodes (up to 64), but also\r\nan on-chip analysis that will allow to reduce the quantity of data by a factor of 20x, by selecting only the\r\ninteresting portions. The platform will be based on a ZedBoard embedding a Zynq (FPGA + ARM processor in\r\none die). This data reduction will allow to save memory, and as a result allow the system to run autonomously\r\nfor a longer period of time. Connection will be supplied by a Wifi link in order to transfer data to a PC, however\r\ngaining autonomy will imply a more reliable system in the sense that if the connection is lost at some point,\r\ndata can be stored for up to 3 hours without losing any important information.\r\nData acquisition will be done by an Intan chip that translates raw voltages from the electrode array onto serial\r\ndigital data that is sent to an FPGA. The processing performed on-chip will consist in signal filtering of the raw\r\ndata, spike detection, noise rejection, and field potential frequency analysis.\r\nFinally a software will also be developed so as to let a user control the embedded platform and to visualize the\r\nanalysis results.\r\nThis project will imply a validation stage, performed by biologists, to ensure the system not only works with\r\nrespect to the specifications, but is also usable by end users."},"de":{"id":11145,"title":"SpikeOnChip: Analyse on-line et on-chip d'activit\u00e9 neuronale","description":"The last decade has witnessed a renewed interest for in vitro approaches in the fields of drug discovery and\r\ntoxicity testing. One very promising approach is the use of engineered human neural tissue fabricated from iPS\r\ncells. To ensure the rapidity of the tests in neural tissues the traditional chemical, cytosolic and histologic read-\r\nouts have been replaced by an electrophysiological read-out, i.e. the recording of the electrical activity of\r\nneurons using smart Petri dishes that incorporate electrode arrays. A big challenge for recording such activity\r\nis the very large amount of data generated by the electrode arrays, resulting in cumbersome and long data\r\nanalysis to be performed in order to get the final experimental results, and the reliability of the systems.\r\nWithin this context, the aim of the SpikeOnChip project is to develop a platform for efficient processing and\r\nstorage of neuronal spike activities. It will not only offer recording of observed electrodes (up to 64), but also\r\nan on-chip analysis that will allow to reduce the quantity of data by a factor of 20x, by selecting only the\r\ninteresting portions. The platform will be based on a ZedBoard embedding a Zynq (FPGA + ARM processor in\r\none die). This data reduction will allow to save memory, and as a result allow the system to run autonomously\r\nfor a longer period of time. Connection will be supplied by a Wifi link in order to transfer data to a PC, however\r\ngaining autonomy will imply a more reliable system in the sense that if the connection is lost at some point,\r\ndata can be stored for up to 3 hours without losing any important information.\r\nData acquisition will be done by an Intan chip that translates raw voltages from the electrode array onto serial\r\ndigital data that is sent to an FPGA. The processing performed on-chip will consist in signal filtering of the raw\r\ndata, spike detection, noise rejection, and field potential frequency analysis.\r\nFinally a software will also be developed so as to let a user control the embedded platform and to visualize the\r\nanalysis results.\r\nThis project will imply a validation stage, performed by biologists, to ensure the system not only works with\r\nrespect to the specifications, but is also usable by end users."}},"id":73396,"acronym":"SpikeOnChip \/ MED","mainTitle":"SpikeOnChip: Analyse on-line et on-chip d'activit\u00e9 neuronale","mainDescription":"The last decade has witnessed a renewed interest for in vitro approaches in the fields of drug discovery and\r\ntoxicity testing. One very promising approach is the use of engineered human neural tissue fabricated from iPS\r\ncells. To ensure the rapidity of the tests in neural tissues the traditional chemical, cytosolic and histologic read-\r\nouts have been replaced by an electrophysiological read-out, i.e. the recording of the electrical activity of\r\nneurons using smart Petri dishes that incorporate electrode arrays. A big challenge for recording such activity\r\nis the very large amount of data generated by the electrode arrays, resulting in cumbersome and long data\r\nanalysis to be performed in order to get the final experimental results, and the reliability of the systems.\r\nWithin this context, the aim of the SpikeOnChip project is to develop a platform for efficient processing and\r\nstorage of neuronal spike activities. It will not only offer recording of observed electrodes (up to 64), but also\r\nan on-chip analysis that will allow to reduce the quantity of data by a factor of 20x, by selecting only the\r\ninteresting portions. The platform will be based on a ZedBoard embedding a Zynq (FPGA + ARM processor in\r\none die). This data reduction will allow to save memory, and as a result allow the system to run autonomously\r\nfor a longer period of time. Connection will be supplied by a Wifi link in order to transfer data to a PC, however\r\ngaining autonomy will imply a more reliable system in the sense that if the connection is lost at some point,\r\ndata can be stored for up to 3 hours without losing any important information.\r\nData acquisition will be done by an Intan chip that translates raw voltages from the electrode array onto serial\r\ndigital data that is sent to an FPGA. The processing performed on-chip will consist in signal filtering of the raw\r\ndata, spike detection, noise rejection, and field potential frequency analysis.\r\nFinally a software will also be developed so as to let a user control the embedded platform and to visualize the\r\nanalysis results.\r\nThis project will imply a validation stage, performed by biologists, to ensure the system not only works with\r\nrespect to the specifications, but is also usable by end users.","value":"143774.00","finished":true,"pilier":6,"url":null,"keywords":"Data Analysis, Electrophysiology, FGPA, In vitro, Micro-Electrode Arrays, Neuronal Monitoring, Signal processing, Software, Spikes","disciplines":[],"axes":[],"partners":[{"id":1843689,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"ReDS","class":"academique"},{"id":1843690,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1843691,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"FR - EIA - Institut iSIS","class":"academique"},{"id":1843692,"name":"Thoma Yann","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"ReDS","class":"academique"}],"collaborators":[{"id":7788405,"role":"RP","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"yann.thoma","project":73396},{"id":7788406,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"rick.wertenbr","project":73396},{"id":7788407,"role":"CO","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"roland.scherwey","project":73396},{"id":7788408,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"mike.meury","project":73396},{"id":7788409,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":73396},{"id":7788410,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":73396},{"id":7788411,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"daniel.gachet","project":73396}],"dataHub":true,"startAt":"2017-04-01T00:00:00+02:00","endAt":"2018-09-30T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7788265,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":6337,"title":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","description":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS (central nervous system) drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells (BCEC) differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n"},"en":{"id":6338,"title":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","description":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS (central nervous system) drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells (BCEC) differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n"},"de":{"id":6339,"title":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","description":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS (central nervous system) drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells (BCEC) differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n"}},"id":31513,"acronym":"MICROBBB2","mainTitle":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","mainDescription":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS (central nervous system) drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells (BCEC) differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n","value":"65000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1843648,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"VS - Institut Sciences du vivant","class":"academique"},{"id":1843649,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7788262,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"anne.walker","project":31513},{"id":7788263,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"sandrine.rutz","project":31513},{"id":7788264,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"bruno.schnyder","project":31513},{"id":7788265,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":31513}],"dataHub":true,"startAt":"2012-01-01T00:00:00+01:00","endAt":"2012-12-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7787584,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":7504,"title":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","description":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)"},"en":{"id":7505,"title":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","description":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)"},"de":{"id":7506,"title":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","description":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)"}},"id":38396,"acronym":"13IMA-S38396-RadioBeam","mainTitle":"A Microfluidic in-vitro perfusion-cell for radiooncological pharmaceutical testing","mainDescription":"Radiobeam Abstract\r\nProblem Current radiopharmaceutical testing for Ion beam cancer therapy (IBCT) requires prohibitively expensive large accelerator systems and animal models. \r\nThe project will construct a proof of concept test system for brain tumour tissue models using co-cultured fluorescent-marked tumour- and normal cells. The perfusion cell is based on a microfluidic circuit allowing diagnosis with in-situ fluorescence confocal microscopy) of neural cells. This will allow nutrient and pharmaceutical preparations to be introduced during irradiation.\r\nUniqueness  Use of multi-cell type brain tissue cultures with low-energy (MeV) ion beam irradiation is an completely new and low-cost way for realistic studies of the neural cellular-level activity representative of the site of tumour eradication deep inside the patients brain. This is inaccessible to both in-vivo studies and single-cell irradiation (where intercellular cell communication il limited)","value":"250000.00","finished":true,"pilier":6,"url":null,"keywords":"Analyses microbiologiques","disciplines":[],"axes":[],"partners":[{"id":1843316,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1843317,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"Ing\u00e9nierie des surfaces","class":"academique"},{"id":1843318,"name":"Whitlow Harry","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"Ing\u00e9nierie des surfaces","class":"academique"}],"collaborators":[{"id":7787578,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"alexandr.kaempfer","project":38396},{"id":7787579,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"christia.broggini","project":38396},{"id":7787580,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"catherin.csefalva","project":38396},{"id":7787581,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"claudio.prieur","project":38396},{"id":7787582,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"stephan.ramseyer","project":38396},{"id":7787583,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":38396},{"id":7787584,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":38396}],"dataHub":true,"startAt":"2013-11-01T00:00:00+01:00","endAt":"2015-10-31T00:00:00+01:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7786840,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":7597,"title":"In vitro models for toxicity assessment\r\n","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and"},"en":{"id":7598,"title":"In vitro models for toxicity assessment\r\n","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and"},"de":{"id":7599,"title":"In vitro models for toxicity assessment\r\n","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and"}},"id":38824,"acronym":"SCAHT4_2014","mainTitle":"In vitro models for toxicity assessment\r\n","mainDescription":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \r\nGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, and","value":"340000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7786837,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":38824},{"id":7786838,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":38824},{"id":7786839,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":38824},{"id":7786840,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":38824}],"dataHub":true,"startAt":"2014-04-01T00:00:00+02:00","endAt":"2014-12-31T00:00:00+01:00","fundingSource":"UNIGE; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7786654,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":6004,"title":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","description":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication."},"en":{"id":6005,"title":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","description":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication."},"de":{"id":6006,"title":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","description":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication."}},"id":30520,"acronym":"SCAHT2","mainTitle":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","mainDescription":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication.","value":"123000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1842854,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1842855,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7786654,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":30520},{"id":7786655,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"sylvaine.janin","project":30520}],"dataHub":true,"startAt":"2011-11-01T00:00:00+01:00","endAt":"2012-10-31T00:00:00+01:00","fundingSource":"SCAHT","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7786585,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":7042,"title":"In vitro models for toxicity assessement.","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an"},"en":{"id":7043,"title":"In vitro models for toxicity assessement.","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an"},"de":{"id":7044,"title":"In vitro models for toxicity assessement.","description":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an"}},"id":36062,"acronym":"SCAHT 3","mainTitle":"In vitro models for toxicity assessement.","mainDescription":"\"3 Neurotoxicology in vitro\r\n3.2 Human in vitro 2D and 3D models of mature neural networks for Neurotoxicity assessment\r\n\r\nProject Leader: Luc Stoppini\r\n Partners: F. Tschudi-Monnet; C. Degeyter; Alex Scherl\r\nFinal histological characterization of 2D and 3 D human neural networks: \r\nWe have generated human neural cells and tissue derived from hESCs. We will perform the final characterization of the different 2D and 3 D neural cultures.\r\nImmunostainings of the different neural makers to assess the presence and the organization of the different cells types (GFAP: for astrocytes; CNPase and MBP for oligodendrocytes; MAP2, NF,NeuN for neurones). We will also perform some electron microscopy studies to assess the precise morphology of the differentiated nervous tissues.\r\nDeliverable: Report on the histological characterization 01.01.2013\r\n31.05.2013\r\nFunctional Characterization of the neural networks generated from hESCs by electrophysiological studies: \r\nElectrophysiological recordings will be performed using neural tissues generated from hESCs and laid down onto MEAs. Spontaneous as well as evoked field potentials will be recorded in control nervous tissues and after exposure of the neuro-glial networks to reference pharmacological molecules to verify that the nervous tissues are responding similarly to primary neural tissues.\r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization. 01.01.2013\r\n31.06.2013\r\nAcute neurotoxicity studies: \r\nAcute dose-responses of neurotoxicants will be performed in 3D human neural networks to assess their effects on the neuronal activity in vitro by means of electrophysiological M.E.A. recordings. \r\nDeliverable: Report on the 3D neural tissue electrophysiological characterization for reference neurotoxic compounds. 01.07.2013\r\n31.12.2013\r\nGene expression profile in 3D neural tissues: \rGene expression profile: We will verify gene expression toxicity signatures using different types of xenobiotics (control and known to induce adverse effects on neural tissues). Human neuro-glial networks will be treated acutely or repeatedly with different concentrations of a series of different types of neurotoxicants. mRNA will be isolated at different culture time points and measured by RT-qPCR. \r\nDeliverable: Report on the 3D neural tissue gene profile of specific markers in control and using reference neurotoxic molecules. 01.04.2013\r\n31.12.2013\r\nProteomic analyses of 3D human neural tissues: \r\nThe proteomic analysis profile will be performed in control conditions and after treatment of 3 D human neural tissues with reference neurotoxic molecules.\r\nDeliverable: Report on proteomic neurotoxic profile of 3D human neural tissues. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using calcium mobilization assay: \r\nMeasurement of calcium mobilization: Variations in the concentration of intracellular calcium, which is known to trigger a number of events including the release of synaptic transmitter, will be measured using Fluo-4 Flexstation Calcium assay kit. Human neuronal cells will be grown in 96 well plates to fit to the workflow system. Reference toxic molecules will be tested to validate the approach.\r\nDeliverable: Report on the validation of the Calcium mobilization as a functional assay to assess neurotoxicity. 01.03.2013\r\n31.12.2013\r\nFunctional activities of 2D neural networks using Neurotransmitter Transporter Uptake Assay: \r\nHomogeneous Neurotransmitter Transporter Uptake Assay: The assay includes a fluorescent indicator dye that mimics the neurotransmitters serotonin, norepinephrine, and dopamine which are actively transported into the cells via the specific neurotransmitter transporters. The fluorescent substrate that mimics the biogenic amine neurotransmitters is then taken up into the cell through those specific transporters, resulting in increased intracellular fluorescence intensity. This homogeneous, fluorescent assay is robust, sensitive, and specific, an","value":"340000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7786581,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":36062},{"id":7786582,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":36062},{"id":7786583,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":36062},{"id":7786584,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"herve.sthioul","project":36062},{"id":7786585,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":36062}],"dataHub":true,"startAt":"2013-01-01T00:00:00+01:00","endAt":"2014-06-30T00:00:00+02:00","fundingSource":"hepia inSTI; Universit\u00e9 de Gen\u00e8ve; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7786201,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":6415,"title":"NeuroSpectrum\r\n","description":"The central nervous system (CNS) is a very complicated system with hundreds of different active molecules involved in numerous processes in different anatomical and functional parts of the brain. The time course of synaptic currents is one of the main factors determining how a single neuron integrates information coming from different inputs. Establishing the temporal and concentration profiles of neurotransmitters during synaptic release is an essential step to monitor inter-neuronal communications in the central nervous system in normal or pathological conditions. We propose to develop a new in vitro assay that will allow us, by measuring the levels of neurotransmitters released from human neural networks within a 3D neural model developed and produced by Neurix (MiniBrain), to assess the beneficial or deleterious effects of new therapeutically compounds or chemicals found in our food and our environment. The profiling of neurotransmitters released from human neural tissues will thus represent a more predictive and cost effective tool that will be integrated into pharmaceutical and chemical industry platforms for early safety and neurotoxicology assays. The aim of this project is to deliver a functional in vitro assay for neurotoxicity assessment which will be commercialized by Neurix. \r\n"},"en":{"id":6416,"title":"NeuroSpectrum\r\n","description":"The central nervous system (CNS) is a very complicated system with hundreds of different active molecules involved in numerous processes in different anatomical and functional parts of the brain. The time course of synaptic currents is one of the main factors determining how a single neuron integrates information coming from different inputs. Establishing the temporal and concentration profiles of neurotransmitters during synaptic release is an essential step to monitor inter-neuronal communications in the central nervous system in normal or pathological conditions. We propose to develop a new in vitro assay that will allow us, by measuring the levels of neurotransmitters released from human neural networks within a 3D neural model developed and produced by Neurix (MiniBrain), to assess the beneficial or deleterious effects of new therapeutically compounds or chemicals found in our food and our environment. The profiling of neurotransmitters released from human neural tissues will thus represent a more predictive and cost effective tool that will be integrated into pharmaceutical and chemical industry platforms for early safety and neurotoxicology assays. The aim of this project is to deliver a functional in vitro assay for neurotoxicity assessment which will be commercialized by Neurix. \r\n"},"de":{"id":6417,"title":"NeuroSpectrum\r\n","description":"The central nervous system (CNS) is a very complicated system with hundreds of different active molecules involved in numerous processes in different anatomical and functional parts of the brain. The time course of synaptic currents is one of the main factors determining how a single neuron integrates information coming from different inputs. Establishing the temporal and concentration profiles of neurotransmitters during synaptic release is an essential step to monitor inter-neuronal communications in the central nervous system in normal or pathological conditions. We propose to develop a new in vitro assay that will allow us, by measuring the levels of neurotransmitters released from human neural networks within a 3D neural model developed and produced by Neurix (MiniBrain), to assess the beneficial or deleterious effects of new therapeutically compounds or chemicals found in our food and our environment. The profiling of neurotransmitters released from human neural tissues will thus represent a more predictive and cost effective tool that will be integrated into pharmaceutical and chemical industry platforms for early safety and neurotoxicology assays. The aim of this project is to deliver a functional in vitro assay for neurotoxicity assessment which will be commercialized by Neurix. \r\n"}},"id":31942,"acronym":"NeuroSpectrum","mainTitle":"NeuroSpectrum\r\n","mainDescription":"The central nervous system (CNS) is a very complicated system with hundreds of different active molecules involved in numerous processes in different anatomical and functional parts of the brain. The time course of synaptic currents is one of the main factors determining how a single neuron integrates information coming from different inputs. Establishing the temporal and concentration profiles of neurotransmitters during synaptic release is an essential step to monitor inter-neuronal communications in the central nervous system in normal or pathological conditions. We propose to develop a new in vitro assay that will allow us, by measuring the levels of neurotransmitters released from human neural networks within a 3D neural model developed and produced by Neurix (MiniBrain), to assess the beneficial or deleterious effects of new therapeutically compounds or chemicals found in our food and our environment. The profiling of neurotransmitters released from human neural tissues will thus represent a more predictive and cost effective tool that will be integrated into pharmaceutical and chemical industry platforms for early safety and neurotoxicology assays. The aim of this project is to deliver a functional in vitro assay for neurotoxicity assessment which will be commercialized by Neurix. \r\n","value":"579104.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1842619,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1842620,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"Universit\u00e9 de Gen\u00e8ve","class":"academique"},{"id":1842621,"name":null,"confidential":false,"types":[{"id":2,"code":"TER"},{"id":5,"code":"TERRAIN"}],"institution":"Neurix","class":"professionnel"},{"id":1842622,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"Universit\u00e9 de Gen\u00e8ve, Pharma","class":"academique"},{"id":1842623,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7786199,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":31942},{"id":7786200,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"sandrine.rutz","project":31942},{"id":7786201,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":31942}],"dataHub":true,"startAt":"2012-01-01T00:00:00+01:00","endAt":"2014-04-30T00:00:00+02:00","fundingSource":"CTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7764635,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":9250,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":9251,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":9252,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":48805,"acronym":"SCAHT-5","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"168095.23","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7764632,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":48805},{"id":7764633,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":48805},{"id":7764634,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":48805},{"id":7764635,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":48805}],"dataHub":true,"startAt":"2015-01-01T00:00:00+01:00","endAt":"2015-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7763668,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":4963,"title":"Multi Organ Chip for Human cell based Alternative testing ","description":"MOCHA will develop a multi-organ device enabling in vitro long-term and systemic toxicity testing. The MOCHA biochip will mimic interaction between human body organs, by assembling in a modular way several toxin-sensitive tissues, serially interconnected by micro-fluidics. Using human cells from various origins, MOCHA will develop 4 tissues, most relevant for systemic toxicity, and assess their suitability for repeated dose toxicity on the multi-organ biochip.\r\nNon-invasive sensors\/biosensors will be embedded on the chip, when suitable as regards miniaturisation and cost. More complex read-out systems will be integrated in a prototype test platform that will enable to control the multi-organ biochips, capture of biochemical, structural and electrophysiological parameters, and data storage and processing.\r\nThe project will also engineer and assess synthetic and natural scaffolds to reproduce 3D environments suitable for long-term culture.\r\nIn addition, MOCHA will develop novel human cell barrier models relevant to systemic exposure for the Blood-Brain barrier and the Epithelial Lung barrier, suitable for integration on the multi-organ device.\r\nThe consortium will start from an extensive know-how in micro-organ chip design, (bio-) sensors, engineering of human target and metabolising cells, cellular barrier research, design of scaffolds, and assessment of alternative testing methods.\r\nThe global aim of the project is to deliver prototypes of multi-organ devices integrating most relevant human tissues for repeated dose toxicity testing, conceived for high-throughput (semi-automated processing of 12 parallel biochip devices), ready to enter prevalidation tests.\r\nAlthough MOCHA will have access to all resources required to achieve its aims, the project organisation and workplan are conceived for establishing synergy and exchanges of knowledge with the other ALTERNATIVE TESTING projects in view to\r\noptimise the results of MOCHA and the whole initiative.\r\n"},"en":{"id":4964,"title":"Multi Organ Chip for Human cell based Alternative testing ","description":"MOCHA will develop a multi-organ device enabling in vitro long-term and systemic toxicity testing. The MOCHA biochip will mimic interaction between human body organs, by assembling in a modular way several toxin-sensitive tissues, serially interconnected by micro-fluidics. Using human cells from various origins, MOCHA will develop 4 tissues, most relevant for systemic toxicity, and assess their suitability for repeated dose toxicity on the multi-organ biochip.\r\nNon-invasive sensors\/biosensors will be embedded on the chip, when suitable as regards miniaturisation and cost. More complex read-out systems will be integrated in a prototype test platform that will enable to control the multi-organ biochips, capture of biochemical, structural and electrophysiological parameters, and data storage and processing.\r\nThe project will also engineer and assess synthetic and natural scaffolds to reproduce 3D environments suitable for long-term culture.\r\nIn addition, MOCHA will develop novel human cell barrier models relevant to systemic exposure for the Blood-Brain barrier and the Epithelial Lung barrier, suitable for integration on the multi-organ device.\r\nThe consortium will start from an extensive know-how in micro-organ chip design, (bio-) sensors, engineering of human target and metabolising cells, cellular barrier research, design of scaffolds, and assessment of alternative testing methods.\r\nThe global aim of the project is to deliver prototypes of multi-organ devices integrating most relevant human tissues for repeated dose toxicity testing, conceived for high-throughput (semi-automated processing of 12 parallel biochip devices), ready to enter prevalidation tests.\r\nAlthough MOCHA will have access to all resources required to achieve its aims, the project organisation and workplan are conceived for establishing synergy and exchanges of knowledge with the other ALTERNATIVE TESTING projects in view to\r\noptimise the results of MOCHA and the whole initiative.\r\n"},"de":{"id":4965,"title":"Multi Organ Chip for Human cell based Alternative testing ","description":"MOCHA will develop a multi-organ device enabling in vitro long-term and systemic toxicity testing. The MOCHA biochip will mimic interaction between human body organs, by assembling in a modular way several toxin-sensitive tissues, serially interconnected by micro-fluidics. Using human cells from various origins, MOCHA will develop 4 tissues, most relevant for systemic toxicity, and assess their suitability for repeated dose toxicity on the multi-organ biochip.\r\nNon-invasive sensors\/biosensors will be embedded on the chip, when suitable as regards miniaturisation and cost. More complex read-out systems will be integrated in a prototype test platform that will enable to control the multi-organ biochips, capture of biochemical, structural and electrophysiological parameters, and data storage and processing.\r\nThe project will also engineer and assess synthetic and natural scaffolds to reproduce 3D environments suitable for long-term culture.\r\nIn addition, MOCHA will develop novel human cell barrier models relevant to systemic exposure for the Blood-Brain barrier and the Epithelial Lung barrier, suitable for integration on the multi-organ device.\r\nThe consortium will start from an extensive know-how in micro-organ chip design, (bio-) sensors, engineering of human target and metabolising cells, cellular barrier research, design of scaffolds, and assessment of alternative testing methods.\r\nThe global aim of the project is to deliver prototypes of multi-organ devices integrating most relevant human tissues for repeated dose toxicity testing, conceived for high-throughput (semi-automated processing of 12 parallel biochip devices), ready to enter prevalidation tests.\r\nAlthough MOCHA will have access to all resources required to achieve its aims, the project organisation and workplan are conceived for establishing synergy and exchanges of knowledge with the other ALTERNATIVE TESTING projects in view to\r\noptimise the results of MOCHA and the whole initiative.\r\n"}},"id":25847,"acronym":"MOCHA","mainTitle":"Multi Organ Chip for Human cell based Alternative testing ","mainDescription":"MOCHA will develop a multi-organ device enabling in vitro long-term and systemic toxicity testing. The MOCHA biochip will mimic interaction between human body organs, by assembling in a modular way several toxin-sensitive tissues, serially interconnected by micro-fluidics. Using human cells from various origins, MOCHA will develop 4 tissues, most relevant for systemic toxicity, and assess their suitability for repeated dose toxicity on the multi-organ biochip.\r\nNon-invasive sensors\/biosensors will be embedded on the chip, when suitable as regards miniaturisation and cost. More complex read-out systems will be integrated in a prototype test platform that will enable to control the multi-organ biochips, capture of biochemical, structural and electrophysiological parameters, and data storage and processing.\r\nThe project will also engineer and assess synthetic and natural scaffolds to reproduce 3D environments suitable for long-term culture.\r\nIn addition, MOCHA will develop novel human cell barrier models relevant to systemic exposure for the Blood-Brain barrier and the Epithelial Lung barrier, suitable for integration on the multi-organ device.\r\nThe consortium will start from an extensive know-how in micro-organ chip design, (bio-) sensors, engineering of human target and metabolising cells, cellular barrier research, design of scaffolds, and assessment of alternative testing methods.\r\nThe global aim of the project is to deliver prototypes of multi-organ devices integrating most relevant human tissues for repeated dose toxicity testing, conceived for high-throughput (semi-automated processing of 12 parallel biochip devices), ready to enter prevalidation tests.\r\nAlthough MOCHA will have access to all resources required to achieve its aims, the project organisation and workplan are conceived for establishing synergy and exchanges of knowledge with the other ALTERNATIVE TESTING projects in view to\r\noptimise the results of MOCHA and the whole initiative.\r\n","value":"34800.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1836098,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7763668,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":25847}],"dataHub":true,"startAt":"2010-01-01T00:00:00+01:00","endAt":"2010-05-31T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7763443,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":5545,"title":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","description":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n"},"en":{"id":5546,"title":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","description":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n"},"de":{"id":5547,"title":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","description":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n"}},"id":28613,"acronym":"MicroBBB","mainTitle":"An Integrated Microfabricated Device for Dual Microdialysis and in vitro Blood-Brain Barrier","mainDescription":"One of the most challenging aspects of drug development is strategy testing. Experiments on whole animals are expensive, raise ethical issues and may not predict effects in humans. Thus, in vitro models that can realistically and inexpensively predict human response to various drug administration and toxic chemical exposure are needed.\r\nThe market for neuropharmaceuticals is regarded as one of the potentially largest sectors of the global pharmaceutical market owing to the increase in average life expectancy and that many neurological disorders have been largely refractory to pharmacotherapy. The value of many promising CNS drug candidates is diminished by the presence at the level of the cerebral capillaries of the Blood-Brain Barrier (BBB) whose physiological function is to maintain brain homeostasis and to provide a defense against blood-borne toxics or infective agents.\r\nExposed to inductive central nervous system factors, brain capillary endothelial cells differentiate into a BBB phenotype based on physical and metabolic properties. Cell culture systems have been developed to reproduce key properties of the BBB and to allow for testing of mechanisms of CNS drug permeation. An improved understanding of neurovascular interactions that exist between BBB and brain may provide novel and more effective strategies to treat neurological disorders. Therefore, the development of a human microscale 3D tissue analogue of neurovascular unit would be of enormous interest to researchers and pharmaceutical companies. Furthermore there is a need in the field of alternative strategy's development for toxicological evaluation to allow completion of REACH program and the 7th amendment to the cosmetics directive in accordance to 3R's. \r\nOur system will consist of a co-culture of human endothelial cells and brain-like tissue culture derived from human embryonic stem cells embedded within microfluidic and microdialysis perfusion systems to biomimic a Neurovascular unit. Our goal is focus on the development of an innovative and relevant model for a multitude of applications, foremost among them experimental screening to identify compounds (new drug candidates, chemicals, cosmetics, nutraceuticals, and consumer products) that have lowest risk for toxicity and highest probability of success.\r\n","value":"80000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1835939,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"VS - Institut Sciences du vivant","class":"academique"},{"id":1835940,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1835941,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7763437,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"anne.walker","project":28613},{"id":7763438,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"ivan.coupy","project":28613},{"id":7763439,"role":"CO","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"wilfried.andlauer","project":28613},{"id":7763440,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"sandrine.rutz","project":28613},{"id":7763441,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"philippe.passerau","project":28613},{"id":7763442,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"bruno.schnyder","project":28613},{"id":7763443,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":28613}],"dataHub":true,"startAt":"2012-01-01T00:00:00+01:00","endAt":"2013-04-30T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7762528,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":5617,"title":"Etude de la repousse nerveuse sur des polym\u00e8res trait\u00e9s par des faisceaux ioniques","description":"Nous proposons de d\u00e9velopper un nouveau type de support\/d\u00e9monstrateur servant de guide pour la r\u00e9g\u00e9n\u00e9ration des fibres de cellules nerveuses apr\u00e8s une l\u00e9sion de nerfs p\u00e9riph\u00e9riques ou centraux. Nous envisageons de traiter diff\u00e9rents types de polym\u00e8res poreux (membranes de  PET, PC et PTFE) par des faisceaux ioniques pour modifier les caract\u00e9ristiques des surfaces de ces mat\u00e9riaux dans le but de favoriser l'adh\u00e9sion cellulaire, la survie la formation et la repousse axonale. \r\nLes caract\u00e9ristiques de bio-compatibilit\u00e9, bio-reconnaissance ou bio-fonctionnalit\u00e9s des membranes modifi\u00e9es par les traitements ioniques seront compar\u00e9es \u00e0 des membranes de m\u00eame mat\u00e9riaux ayant \u00e9t\u00e9 recouvertes de mol\u00e9cules chimiques (poly-lysine, laminine) qui sont connues pour favoriser l'adh\u00e9sion ainsi que l'extension neuritiques des cellules nerveuses. Dans ce projet, la validation des mat\u00e9riaux trait\u00e9s sera effectu\u00e9e par l'utilisation d'une lign\u00e9e de cellules nerveuses humaines (RenCell VM) qui exprime un \u00ab reporter \u00bb fluorescent RFP (Red Fluorescent Protein) fusionn\u00e9 au g\u00e8ne de la \u00df-III tubuline. L'utilisation de cette lign\u00e9e permettra ainsi sa visualisation en continue lors du stade d'adh\u00e9sion, de prolif\u00e9ration et de diff\u00e9renciation via l'utilisation de la microscopie en fluorescence. L'irradiation par faisceau ionique de haute \u00e9nergie permet d'am\u00e9liorer  significativement l'adh\u00e9sion cellulaire. En fonction de l'esp\u00e8ce ionique implant\u00e9e, comme le carbone, l'h\u00e9lium on constate une s\u00e9lectivit\u00e9 de la croissance cellulaire. Ainsi par l'utilisation de masques plac\u00e9s entre le faisceau ionique \u00e0 large focale (plusieurs cm2) et le polym\u00e8re cible il sera possible de cr\u00e9er sur celui-ci des zones g\u00e9om\u00e9triques complexes de croissance neuronale.\r\nLes membranes ainsi modifi\u00e9es seront ensuite st\u00e9rilis\u00e9es puis d\u00e9pos\u00e9es dans des bo\u00eetes de p\u00e9tri. Les cellules nerveuses seront ensemenc\u00e9es sur les membranes modifi\u00e9es en surface par traitements ionique ou chimiques, comme cultures contr\u00f4les. Le nombre de cellules ayant adh\u00e9r\u00e9es sur les polym\u00e8res ionis\u00e9s ou ayant subit un rev\u00eatement chimique ainsi que la longueur des fibres nerveuses seront \u00e9valu\u00e9s par un comptage automatique par un logiciel d'imagerie d\u00e9di\u00e9 \u00e0 la microscopie optique (ImageJ, NIH).\r\n"},"en":{"id":5618,"title":"Etude de la repousse nerveuse sur des polym\u00e8res trait\u00e9s par des faisceaux ioniques","description":"Nous proposons de d\u00e9velopper un nouveau type de support\/d\u00e9monstrateur servant de guide pour la r\u00e9g\u00e9n\u00e9ration des fibres de cellules nerveuses apr\u00e8s une l\u00e9sion de nerfs p\u00e9riph\u00e9riques ou centraux. Nous envisageons de traiter diff\u00e9rents types de polym\u00e8res poreux (membranes de  PET, PC et PTFE) par des faisceaux ioniques pour modifier les caract\u00e9ristiques des surfaces de ces mat\u00e9riaux dans le but de favoriser l'adh\u00e9sion cellulaire, la survie la formation et la repousse axonale. \r\nLes caract\u00e9ristiques de bio-compatibilit\u00e9, bio-reconnaissance ou bio-fonctionnalit\u00e9s des membranes modifi\u00e9es par les traitements ioniques seront compar\u00e9es \u00e0 des membranes de m\u00eame mat\u00e9riaux ayant \u00e9t\u00e9 recouvertes de mol\u00e9cules chimiques (poly-lysine, laminine) qui sont connues pour favoriser l'adh\u00e9sion ainsi que l'extension neuritiques des cellules nerveuses. Dans ce projet, la validation des mat\u00e9riaux trait\u00e9s sera effectu\u00e9e par l'utilisation d'une lign\u00e9e de cellules nerveuses humaines (RenCell VM) qui exprime un \u00ab reporter \u00bb fluorescent RFP (Red Fluorescent Protein) fusionn\u00e9 au g\u00e8ne de la \u00df-III tubuline. L'utilisation de cette lign\u00e9e permettra ainsi sa visualisation en continue lors du stade d'adh\u00e9sion, de prolif\u00e9ration et de diff\u00e9renciation via l'utilisation de la microscopie en fluorescence. L'irradiation par faisceau ionique de haute \u00e9nergie permet d'am\u00e9liorer  significativement l'adh\u00e9sion cellulaire. En fonction de l'esp\u00e8ce ionique implant\u00e9e, comme le carbone, l'h\u00e9lium on constate une s\u00e9lectivit\u00e9 de la croissance cellulaire. Ainsi par l'utilisation de masques plac\u00e9s entre le faisceau ionique \u00e0 large focale (plusieurs cm2) et le polym\u00e8re cible il sera possible de cr\u00e9er sur celui-ci des zones g\u00e9om\u00e9triques complexes de croissance neuronale.\r\nLes membranes ainsi modifi\u00e9es seront ensuite st\u00e9rilis\u00e9es puis d\u00e9pos\u00e9es dans des bo\u00eetes de p\u00e9tri. Les cellules nerveuses seront ensemenc\u00e9es sur les membranes modifi\u00e9es en surface par traitements ionique ou chimiques, comme cultures contr\u00f4les. Le nombre de cellules ayant adh\u00e9r\u00e9es sur les polym\u00e8res ionis\u00e9s ou ayant subit un rev\u00eatement chimique ainsi que la longueur des fibres nerveuses seront \u00e9valu\u00e9s par un comptage automatique par un logiciel d'imagerie d\u00e9di\u00e9 \u00e0 la microscopie optique (ImageJ, NIH).\r\n"},"de":{"id":5619,"title":"Etude de la repousse nerveuse sur des polym\u00e8res trait\u00e9s par des faisceaux ioniques","description":"Nous proposons de d\u00e9velopper un nouveau type de support\/d\u00e9monstrateur servant de guide pour la r\u00e9g\u00e9n\u00e9ration des fibres de cellules nerveuses apr\u00e8s une l\u00e9sion de nerfs p\u00e9riph\u00e9riques ou centraux. Nous envisageons de traiter diff\u00e9rents types de polym\u00e8res poreux (membranes de  PET, PC et PTFE) par des faisceaux ioniques pour modifier les caract\u00e9ristiques des surfaces de ces mat\u00e9riaux dans le but de favoriser l'adh\u00e9sion cellulaire, la survie la formation et la repousse axonale. \r\nLes caract\u00e9ristiques de bio-compatibilit\u00e9, bio-reconnaissance ou bio-fonctionnalit\u00e9s des membranes modifi\u00e9es par les traitements ioniques seront compar\u00e9es \u00e0 des membranes de m\u00eame mat\u00e9riaux ayant \u00e9t\u00e9 recouvertes de mol\u00e9cules chimiques (poly-lysine, laminine) qui sont connues pour favoriser l'adh\u00e9sion ainsi que l'extension neuritiques des cellules nerveuses. Dans ce projet, la validation des mat\u00e9riaux trait\u00e9s sera effectu\u00e9e par l'utilisation d'une lign\u00e9e de cellules nerveuses humaines (RenCell VM) qui exprime un \u00ab reporter \u00bb fluorescent RFP (Red Fluorescent Protein) fusionn\u00e9 au g\u00e8ne de la \u00df-III tubuline. L'utilisation de cette lign\u00e9e permettra ainsi sa visualisation en continue lors du stade d'adh\u00e9sion, de prolif\u00e9ration et de diff\u00e9renciation via l'utilisation de la microscopie en fluorescence. L'irradiation par faisceau ionique de haute \u00e9nergie permet d'am\u00e9liorer  significativement l'adh\u00e9sion cellulaire. En fonction de l'esp\u00e8ce ionique implant\u00e9e, comme le carbone, l'h\u00e9lium on constate une s\u00e9lectivit\u00e9 de la croissance cellulaire. Ainsi par l'utilisation de masques plac\u00e9s entre le faisceau ionique \u00e0 large focale (plusieurs cm2) et le polym\u00e8re cible il sera possible de cr\u00e9er sur celui-ci des zones g\u00e9om\u00e9triques complexes de croissance neuronale.\r\nLes membranes ainsi modifi\u00e9es seront ensuite st\u00e9rilis\u00e9es puis d\u00e9pos\u00e9es dans des bo\u00eetes de p\u00e9tri. Les cellules nerveuses seront ensemenc\u00e9es sur les membranes modifi\u00e9es en surface par traitements ionique ou chimiques, comme cultures contr\u00f4les. Le nombre de cellules ayant adh\u00e9r\u00e9es sur les polym\u00e8res ionis\u00e9s ou ayant subit un rev\u00eatement chimique ainsi que la longueur des fibres nerveuses seront \u00e9valu\u00e9s par un comptage automatique par un logiciel d'imagerie d\u00e9di\u00e9 \u00e0 la microscopie optique (ImageJ, NIH).\r\n"}},"id":29011,"acronym":"Regener-Ion","mainTitle":"Etude de la repousse nerveuse sur des polym\u00e8res trait\u00e9s par des faisceaux ioniques","mainDescription":"Nous proposons de d\u00e9velopper un nouveau type de support\/d\u00e9monstrateur servant de guide pour la r\u00e9g\u00e9n\u00e9ration des fibres de cellules nerveuses apr\u00e8s une l\u00e9sion de nerfs p\u00e9riph\u00e9riques ou centraux. Nous envisageons de traiter diff\u00e9rents types de polym\u00e8res poreux (membranes de  PET, PC et PTFE) par des faisceaux ioniques pour modifier les caract\u00e9ristiques des surfaces de ces mat\u00e9riaux dans le but de favoriser l'adh\u00e9sion cellulaire, la survie la formation et la repousse axonale. \r\nLes caract\u00e9ristiques de bio-compatibilit\u00e9, bio-reconnaissance ou bio-fonctionnalit\u00e9s des membranes modifi\u00e9es par les traitements ioniques seront compar\u00e9es \u00e0 des membranes de m\u00eame mat\u00e9riaux ayant \u00e9t\u00e9 recouvertes de mol\u00e9cules chimiques (poly-lysine, laminine) qui sont connues pour favoriser l'adh\u00e9sion ainsi que l'extension neuritiques des cellules nerveuses. Dans ce projet, la validation des mat\u00e9riaux trait\u00e9s sera effectu\u00e9e par l'utilisation d'une lign\u00e9e de cellules nerveuses humaines (RenCell VM) qui exprime un \u00ab reporter \u00bb fluorescent RFP (Red Fluorescent Protein) fusionn\u00e9 au g\u00e8ne de la \u00df-III tubuline. L'utilisation de cette lign\u00e9e permettra ainsi sa visualisation en continue lors du stade d'adh\u00e9sion, de prolif\u00e9ration et de diff\u00e9renciation via l'utilisation de la microscopie en fluorescence. L'irradiation par faisceau ionique de haute \u00e9nergie permet d'am\u00e9liorer  significativement l'adh\u00e9sion cellulaire. En fonction de l'esp\u00e8ce ionique implant\u00e9e, comme le carbone, l'h\u00e9lium on constate une s\u00e9lectivit\u00e9 de la croissance cellulaire. Ainsi par l'utilisation de masques plac\u00e9s entre le faisceau ionique \u00e0 large focale (plusieurs cm2) et le polym\u00e8re cible il sera possible de cr\u00e9er sur celui-ci des zones g\u00e9om\u00e9triques complexes de croissance neuronale.\r\nLes membranes ainsi modifi\u00e9es seront ensuite st\u00e9rilis\u00e9es puis d\u00e9pos\u00e9es dans des bo\u00eetes de p\u00e9tri. Les cellules nerveuses seront ensemenc\u00e9es sur les membranes modifi\u00e9es en surface par traitements ionique ou chimiques, comme cultures contr\u00f4les. Le nombre de cellules ayant adh\u00e9r\u00e9es sur les polym\u00e8res ionis\u00e9s ou ayant subit un rev\u00eatement chimique ainsi que la longueur des fibres nerveuses seront \u00e9valu\u00e9s par un comptage automatique par un logiciel d'imagerie d\u00e9di\u00e9 \u00e0 la microscopie optique (ImageJ, NIH).\r\n","value":"100000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1835298,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"},{"id":1835299,"name":"","confidential":false,"types":[{"id":4,"code":"CO"}],"institution":"Micro et nano syst\u00e8mes","class":"academique"},{"id":1835300,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"hepia inSTI","class":"academique"}],"collaborators":[{"id":7762527,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"stephan.ramseyer","project":29011},{"id":7762528,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":29011}],"dataHub":true,"startAt":"2012-01-01T00:00:00+01:00","endAt":"2013-04-30T00:00:00+02:00","fundingSource":"HES-SO Rectorat","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7762518,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":4864,"title":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","description":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication."},"en":{"id":4865,"title":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","description":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication."},"de":{"id":4866,"title":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","description":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication."}},"id":24831,"acronym":"SCAHT","mainTitle":"D\u00e9veloppement de mod\u00e8les de toxicologie in vitro pour la d\u00e9couverte de nouveaux biomarqueurs ","mainDescription":"Dans le cadre du centre Suisse de toxicologie, nous proposons de mettre au point des mod\u00e8les bas\u00e9s sur la culture de tissus nerveux et testiculaires pour mettre en \u00e9vidence de nouveaux biomarqueurs lors d'intoxication.","value":"275000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[{"id":1835290,"name":"","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"EIG - IBIO","class":"academique"},{"id":1835291,"name":"Stoppini Luc","confidential":false,"types":[{"id":3,"code":"RP"},{"id":4,"code":"CO"}],"institution":"EIG - IBIO","class":"academique"}],"collaborators":[{"id":7762518,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":24831}],"dataHub":true,"startAt":"2009-11-01T00:00:00+01:00","endAt":"2011-10-31T00:00:00+01:00","fundingSource":"SCAHT","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7760356,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":12466,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":12467,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":12468,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":94184,"acronym":"SCAHT-9","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"240000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7760349,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":94184},{"id":7760350,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":94184},{"id":7760351,"role":"ME","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":94184},{"id":7760352,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"axel.baxarias","project":94184},{"id":7760353,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"yoann.muller","project":94184},{"id":7760354,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":94184},{"id":7760355,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"julien.crovador","project":94184},{"id":7760356,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":94184}],"dataHub":true,"startAt":"2019-01-01T00:00:00+01:00","endAt":"2019-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":7757547,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":10438,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"en":{"id":10439,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"},"de":{"id":10440,"title":"Swiss Centre Human Applied Toxicology.\r\n","description":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n"}},"id":66944,"acronym":"SCAHT-7","mainTitle":"Swiss Centre Human Applied Toxicology.\r\n","mainDescription":"Human in vitro 2D and 3D models of mature neural networks for neurotoxicity assessment.\r\n","value":"240000.00","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":7757544,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"dominiqu.trinchan","project":66944},{"id":7757545,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"laetitia.nikles","project":66944},{"id":7757546,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"adrien.roux","project":66944},{"id":7757547,"role":"RP","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":66944}],"dataHub":true,"startAt":"2017-01-01T00:00:00+01:00","endAt":"2017-12-31T00:00:00+01:00","fundingSource":"SCAHT; hepia inSTI","publications":[],"projectUrl":null,"repo_name":null}}

{"id":340109,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":{"translations":{"fr":{"id":17195,"title":"DeepAPMEA","description":"
Ce projet en collaboration entre HEPIA et la HEIG-VD vise a développer des solutions basées sur des réseaux de neurones artificiels pour analyser et classifier des activités électriques de tissus de neurones. Ces réseaux neuronaux seront également implémentés sur des cicuits FPGA.<\/p>"}},"id":1048850,"acronym":null,"mainTitle":"DeepAPMEA","mainDescription":"
Ce projet en collaboration entre HEPIA et la HEIG-VD vise a développer des solutions basées sur des réseaux de neurones artificiels pour analyser et classifier des activités électriques de tissus de neurones. Ces réseaux neuronaux seront également implémentés sur des cicuits FPGA.<\/p>","value":"150000","finished":true,"pilier":6,"url":null,"keywords":null,"disciplines":[],"axes":[],"partners":[],"collaborators":[{"id":340103,"role":"RP","display":true,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"andres.upeguipo","project":1048850},{"id":340104,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"phillip.geier","project":1048850},{"id":340105,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"flavio.mor","project":1048850},{"id":340106,"role":"CO","display":true,"displayRole":true,"displayFinancialPartner":false,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"andres.perezuri","project":1048850},{"id":340107,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"bruno.studer","project":1048850},{"id":340108,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"diego.barrient","project":1048850},{"id":340109,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"luc.stoppini","project":1048850},{"id":340110,"role":"ME","display":false,"displayRole":true,"displayFinancialPartner":true,"displayAcademicPartner":true,"displayProfessionalPartner":true,"collaborator":"hectorfa.satizaba","project":1048850}],"dataHub":false,"startAt":"2019-05-01T00:00:00+02:00","endAt":"2022-03-31T00:00:00+02:00","fundingSource":"HES-SO","publications":[],"projectUrl":null,"repo_name":null}}

[{"id":10945288606,"position":-1,"master":1,"function":"","title":null,"email":"luc.stoppini@hesge.ch","display":true,"jobLocation":"Campus Biotech - B03-02","phone":"+41 22 558 60 45","phoneVisible":false,"employer":{"translations":{"fr":{"id":23,"name":"Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture de Gen\u00e8ve"}},"id":561,"ldapId":"RORG-HEGE-EPIA","abbreviation":"hepia","link":"http:\/\/www.hesge.ch\/hepia","mail":"RHHEPIA@hesge.ch ","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/logo_hepia-ge.png","gmap":"46.209551, 6.135261","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1054,"type":"adressePrincipale","street":"Rue de la Prairie 4","officeBox":"","country":"CH","city":"1202 Gen\u00e8ve"}],"mainDomain":null,"secondaryDomain":null,"programs":[{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},{"id":22,"empty":false,"name":"BSc HES-SO en G\u00e9nie m\u00e9canique"},{"id":24,"empty":false,"name":"BSc HES-SO en G\u00e9nie civil"},{"id":26,"empty":false,"name":"BA HES-SO en Architecture"},{"id":49,"empty":false,"name":"BSc HES-SO en Technique des b\u00e2timents"},{"id":50,"empty":false,"name":"BSc HES-SO en Ing\u00e9nierie des technologies de l'information"},{"id":51,"empty":false,"name":"BSc HES-SO en Gestion de la nature"},{"id":52,"empty":false,"name":"BSc HES-SO en Architecture du paysage"},{"id":53,"empty":false,"name":"BSc HES-SO en Agronomie"},{"id":79,"empty":false,"name":"BSC HES-SO en Informatique et syst\u00e8mes de communication"},{"id":80,"empty":false,"name":"BSc en Informatique et syst\u00e8mes de communication"}]},"instituts":[],"service":{"translations":{"fr":{"id":23,"name":"Haute \u00e9cole du paysage, d'ing\u00e9nierie et d'architecture de Gen\u00e8ve"}},"id":561,"ldapId":"RORG-HEGE-EPIA","abbreviation":"hepia","link":"http:\/\/www.hesge.ch\/hepia","mail":"RHHEPIA@hesge.ch ","logo":"http:\/\/people.hes-so.ch\/build\/img\/logos\/logo_hepia-ge.png","gmap":"46.209551, 6.135261","type":{"id":3,"name":"Ecole membre"},"addresses":[{"id":1054,"type":"adressePrincipale","street":"Rue de la Prairie 4","officeBox":"","country":"CH","city":"1202 Gen\u00e8ve"}],"mainDomain":null,"secondaryDomain":null,"programs":[{"id":15,"empty":false,"name":"BSc HES-SO en Microtechniques"},{"id":22,"empty":false,"name":"BSc HES-SO en G\u00e9nie m\u00e9canique"},{"id":24,"empty":false,"name":"BSc HES-SO en G\u00e9nie civil"},{"id":26,"empty":false,"name":"BA HES-SO en Architecture"},{"id":49,"empty":false,"name":"BSc HES-SO en Technique des b\u00e2timents"},{"id":50,"empty":false,"name":"BSc HES-SO en Ing\u00e9nierie des technologies de l'information"},{"id":51,"empty":false,"name":"BSc HES-SO en Gestion de la nature"},{"id":52,"empty":false,"name":"BSc HES-SO en Architecture du paysage"},{"id":53,"empty":false,"name":"BSc HES-SO en Agronomie"},{"id":79,"empty":false,"name":"BSC HES-SO en Informatique et syst\u00e8mes de communication"},{"id":80,"empty":false,"name":"BSc en Informatique et syst\u00e8mes de communication"}]},"serviceHesso":null,"branch":{"translations":{"fr":{"id":364,"name":"Microtechniques"}},"id":139430,"abbreviation":"MTEC","type":1,"ldapId":"RACA-TICO-MTEC","parent":{"translations":{"fr":{"id":637,"name":"Technique et IT"}},"id":56625318,"abbreviation":"TeIT","type":0,"ldapId":"RACA-TICO","parent":null}}}]

Ecole(s)

HEPIA

Affichage téléphone

0